Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 5, 2009, Pages 684-690

  Bahadir, Muzeyyen Aslan ^a   Oguz, Aytekin ^a   Uzunlulu, Mehmet ^a   Bahadir, Ozgur ^a  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Metabolic syndrome; Small dense low density lipoprotein cholesterol; Statin

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLIC SYNDROME X; PARTICLE SIZE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WAIST CIRCUMFERENCE;

EID: 73249131989     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.1123     Document Type: Article

References (26)

1. Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol, 2006; 47: 1093-1100
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112: 2735-2752
3. Rizzo M, Berneis K: Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention ? J Atheroscler Thromb, 2005; 12: 237-239
4. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, 1996; 276: 875-881
5. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA, 1996; 276: 882-888
6. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation, 1997; 95: 69-75
7. Rizzo M, Berneis K, Corrado E, Novo S: The significance of low-density-lipoproteins size in vascular diseases. Int Angiol, 2006; 25: 4-9
8. Rizzo M, Berneis K: The clinical relevance of low-densitylipoproteins size modulation by statins. Cardiovasc Drugs Ther, 2006; 20: 205-217
9. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S: Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb, 2004; 11: 278-285
10. International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available at: http://www.idf. org/webdata/does/IDF-Meta-syndrome- definition.pdf. Accessed August 24, 2005
11. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
12. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem, 2001; 47: 266-274
13. Rizzo M, Rini GB, Berneis K: Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Adv Ther, 2007; 24: 575-582
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel ??). JAMA, 2001; 285: 2486-2497
15. Rizzo M, Berneis K: Who needs to care about small, dense low-density lipoproteins ? Int J Clin Pract, 2007; 61: 1949-1956
16. Yoshino G, Hirano T, Kazumi T: Treatment of small dense LDL. J Atheroscler Thromb, 2002; 9: 266-275
17. Nozue T, Michishita I, Ishibashi Y, Ito S, Iwaki T, Mizuguchi I, Miura M, Ito Y, Hirano T: Small dense low-den sity lipoprotein cholesterol is a useful marker of metabolic syndrome in patients with coronary artery disease. J Atheroscler Thromb, 2007; 14: 202-207
18. Gentile M, Panico S, Jossa F, Mattiello A, Ubaldi S, Marotta G, Pauciullo P, Rubba P: Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. Clin Chim Acta, 2008; 388: 179-183
19. Vinik AI: The metabolic basis of atherogenic dyslipidemia. Clin Cornerstone, 2005; 7: 27-35
20. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group: Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther, 2004; 26: 1388-1399
21. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ: Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol, 2008; 101: 315-318
22. Lamarche B, Lemieux I, Després JP: The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab, 1999; 25: 199-211
23. Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima M, Shiraishi Y, Ito Y, Adachi M: The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb, 2007; 14:128-132
24. Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima M, Shiraishi Y, Ito Y, Adachi M: The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb, 2007; 14: 128-132
25. Yoshida A, Kouwaki M, Matsutani Y, Fukuchi Y, Naito M: Usefulness of serum total cholesterol/triglyceride ratio for predicting the presence of small, dense LDL. J Atheroscler Thromb, 2004; 11: 215-219
26. Wägner AM, Pérez A, Sánchez-Quesada JL, Ordóñez-Llanos J: Triglyceride-to-HDL cholesterol ratio in the dyslipidemic classification of type 2 diabetes. Diabetes Care, 2005; 28: 1798-1800